Magic Mushrooms Effective for Treating Depression – Study | British News

Magic mushrooms have the potential to be an effective antidepressant, according to a new study.

Psilocybin – the active ingredient in magic mushrooms – has shown promise in relieving symptoms of depression after one or two doses, with few side effects and no signs of addiction.

However, previous studies have not examined factors that could influence the effectiveness of the psychedelic, such as the dose, whether people have taken psychedelics before, and the type of depression.

To address this issue, researchers examined randomized controlled trials that compared psilocybin with control substances such as a placebo, vitamin B, or microdosed psychedelics.

Her research was published in the medical journal BMJ.

They examined seven studies involving 436 people with depression. The change in their depression was measured using a system called Hedges’ g.

A value of 0.2 indicates a small effect, 0.5 indicates a moderate effect, and 0.8 or more indicates a large effect.

Overall, the people treated with psilocybin achieved a value of 1.64.

Greater improvements were seen in older people, people who had previously used psychedelics, and people with secondary depression (related to an underlying medical condition) rather than primary depression.

The researchers said the results were encouraging, but further research was needed “to clarify the factors that maximize the treatment potential of psilocybin for depression symptoms.”

They said issues such as cost, lack of regulatory guidelines and legal protections surrounding psilocybin treatment need to be clarified before it can be established in clinical practice.

Read more:
Moms on Magic Mushrooms: Why Parents “Microdose”
Magic mushrooms “could help with cancer-related depression”

Follow Sky News on WhatsApp
Follow Sky News on WhatsApp

Keep up to date with the latest news from the UK and around the world by following Sky News

Press here

The consultant psychiatrist Dr. Paul Keedwell described the results as “impressive” and noted the rapid improvement in many patients.

“Longer follow-up would be welcome, and more work needs to be done on optimal dosing,” he said.

“It appears that a strong psychedelic experience is required to achieve the best results.

“The main disadvantage is that some patients find the psychedelic effects unpleasant and care must be taken to maintain a quiet environment during treatment.”

The authors note that because their analysis uses data from different studies, it is not possible to distinguish between people most likely to benefit from psilocybin and those who may instead experience side effects.

Source link